Nykode Therapeutics ASA Total Assets
Nykode Therapeutics ASA total assets. Based on the latest financial reports, Nykode Therapeutics ASA (NYKD) holds total assets worth Nkr86.11 Million NOK (≈ $9.06 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see NYKD company net worth for the company's overall valuation and market capitalisation.
Total Assets of Nykode Therapeutics ASA (2016–2025)
Total assets of Nykode Therapeutics ASA from 2016 to 2025. This chart illustrates how Nykode Therapeutics ASA's total assets have evolved over time, based on quarterly financial data. See Nykode Therapeutics ASA share price for real-time trading data and today's change.
Nykode Therapeutics ASA - Asset Composition Analysis
Nykode Therapeutics ASA Total Assets Breakdown (December 2025)
Nykode Therapeutics ASA total assets breakdown as of December 2025. Nykode Therapeutics ASA's total assets of Nkr86.11 Million consist of 61.9% current assets and 38.1% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr60.29 Million | 60.3% |
| Accounts Receivable | Nkr0.00 | 0.0% |
| Inventory | Nkr0.00 | 0.0% |
| Property, Plant & Equipment | Nkr5.68 Million | 5.7% |
| Intangible Assets | Nkr72.00K | 0.1% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Nykode Therapeutics ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Nykode Therapeutics ASA (NYKD) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nykode Therapeutics ASA's current assets represent 61.9% of total assets in 2025, a decrease from 99.8% in 2016.
- Cash Position: Cash and equivalents constituted 60.3% of total assets in 2025, up from 11.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is cash and equivalents at 60.3% of total assets.
Nykode Therapeutics ASA Competitors by Total Assets
Key competitors of Nykode Therapeutics ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Nykode Therapeutics ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.52 | 15.21 | 18.47 |
| Quick Ratio | 11.52 | 15.21 | 18.47 |
| Cash Ratio | 0.00 | 14.64 | 1.81 |
| Working Capital | Nkr44.01 Million | Nkr67.97 Million | Nkr1.67 Billion |
Nykode Therapeutics ASA - Advanced Valuation Insights
This section examines the relationship between Nykode Therapeutics ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.13 |
| Latest Market Cap to Assets Ratio | 1.23 |
| Asset Growth Rate (YoY) | -34.9% |
| Total Assets | Nkr99.95 Million |
| Market Capitalization | $123.19 Million USD |
Valuation Analysis
Above Book Valuation: The market values Nykode Therapeutics ASA's assets above their book value (1.23x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Nykode Therapeutics ASA's assets decreased by 34.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nykode Therapeutics ASA (2016–2025)
The table below shows the annual total assets of Nykode Therapeutics ASA from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr99.95 Million ≈ $10.52 Million |
-34.87% |
| 2024-12-31 | Nkr153.48 Million ≈ $16.15 Million |
-26.28% |
| 2023-12-31 | Nkr208.19 Million ≈ $21.91 Million |
-6.00% |
| 2022-12-31 | Nkr221.48 Million ≈ $23.31 Million |
-16.60% |
| 2021-12-31 | Nkr265.56 Million ≈ $27.94 Million |
+15.45% |
| 2020-12-31 | Nkr230.03 Million ≈ $24.21 Million |
-21.51% |
| 2019-12-31 | Nkr293.08 Million ≈ $30.84 Million |
+91.13% |
| 2018-12-31 | Nkr153.34 Million ≈ $16.14 Million |
-28.50% |
| 2017-12-31 | Nkr214.47 Million ≈ $22.57 Million |
+760.35% |
| 2016-12-31 | Nkr24.93 Million ≈ $2.62 Million |
-- |
About Nykode Therapeutics ASA
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication… Read more